Authored Content
The recently launched CHI Catalogue signals payer endorsement of high-cost breakthrough therapies supported by strong clinical evidence, real-world data, and guideline endorsement.
Rare disease patient groups in APAC can amplify their impact through multi-stakeholder collaboration to achieve equitable access for people living with rare diseases.